Bristol Myers Squibb (NYSE:BMY) has recently announced its results for the first quarter, reporting adjusted earnings of $1.80 per share on revenue of $11.2 billion. This revenue marks a 6% ...

Bristol Myers Squibb is scheduled to release its earnings report on Thursday, April 24, 2025. Examining its historical performance, the BMY stock has tended to react negatively after earnings ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Bristol Myers Squibb Co. closed 25.25% below its 52-week high of $63.33, which the company reached on March 11th.

Bristol Myers Squibb (NYSE:BMY) and Bain Capital have announced the establishment of a new independent biopharmaceutical ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

Bristol-Myers Squibb Co.’s chief medical officer is stepping down from his role after six years at the company, a surprise ...

The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.